Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Pentaxim in South African Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged \< 24 hours on the day of inclusion~Exclusion Criteria:~* At visit 01 (screening)~* Illness at a stage that could interfere with trial conduct or completion.~* Any vaccination preceding the trial participation (except Bacille Calmette-Guerin \[BCG\])~* Acute illness on the day of screening. At visit 01 and visit 02 (screening and first study vaccination).~* Planned participation in another clinical trial during the present trial period~* Blood or blood-derived products received since birth.~* Mother known as seropositive to HIV or hepatitis B.~* Known thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current seizures at visit 02 (first study vaccination)~* Participation in another clinical trial preceding the first trial vaccination~* Congenital or acquired immunodeficiency; immunosuppressive therapy such as long-term systemic corticosteroid therapy.~* Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion.~* Any vaccination preceding the first trial vaccination (except BCG)~* History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b and hepatitis B infection (confirmed either clinically, serologically or microbiologically).~* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b and hepatitis B infection with the trial vaccine or another vaccine.~* Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) or acute illness on the day of first vaccination

- Gender: ALL
- Minimum Age: 24 Hours
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).